Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Inhaled Corticosteroids Boost Pneumonia Risk in COPD

Benefits should be weighed against downside, experts say

By Steven Reinberg
HealthDay Reporter


Related Encyclopedia
 border=
Abdominoplasty
Acoustic Neurinoma
Ankle Sprains
Ankylosing Spondylitis
More...

Related Healthscout Videos
 border=
Cancer Treatment for Any Size
Helium Helps Asthmatics Breathe
Fine Tuning for Hearing Impaired
Hungry Heart
More...

Related Animations
 border=
Asthma
Erectile Dysfunction
More...

Related Drug Information
 border=
Advair Diskus
Cialis
Combivent
Flomax
More...

Related News Articles
 border=
Vitamin D Deficiency Linked to Cardiovascular Disease
Low Vitamin D Tied to Estrogen Decline
Caring Through Sharing -- Life Changing Stories
Developmental Delays Linked to Nicotine Gene?
More...

MONDAY, Feb. 9 (HealthDay News) -- The use of inhalers containing corticosteroids to treat chronic obstructive pulmonary disease (COPD) might increase the risk of pneumonia by as much as 70 percent, researchers report.

Inhaled corticosteroids, used to treat asthma, are not approved for use in COPD patients. However, one product that is marketed by GlaxoSmithKline, Advair, combines steroids with a beta-antagonist and is approved to treat COPD. A similar product, Symbicort, marketed by AstraZeneca, is currently under consideration for use in COPD patients.

Text Continues Below



"It is not that we didn't know the potential for these risks, but these risks must be balanced against the uncertain benefits of the drugs providing some symptom relief in these patients," said lead researcher Dr. Sonal Singh, an assistant professor of internal medicine at Wake Forest University Baptist Medical Center.

No one should stop using their inhaler based on this study, Singh said. However, the inhalers are not effective for COPD, "and then you have these substantial risks," he said.

The report is published in the Feb. 9 issue of the Archives of Internal Medicine.

For the study, Singh's team reviewed the findings of 18 clinical trials that included a total of 16,996 people. The researchers looked for cases of pneumonia among people who were using inhaled corticosteroids for at least 24 weeks.

They compared them with people who had used a placebo, and they also compared those who had used a combination of inhaled corticosteroids and long-acting beta-antagonists with those who had used only the long-acting bronchodilator.

The researchers found that people taking corticosteroids alone or in combination with bronchodilators increased their risk of developing pneumonia by 60 to 70 percent. However, this increase in pneumonia was not associated with an increased risk of dying.

Page:  1 | 2 | 3 | Next >>

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 2/9/2009

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake





SOURCES: Sonal Singh, M.D., M.P.H., assistant professor, internal medicine, Wake Forest University Baptist Medical Center, Winston-Salem, N.C.; Norman Edelman, M.D., chief medical officer, American Lung Association, New York City; Katie Neff, spokeswoman, AstraZeneca, Wilmington, Del.; Patty Johnson, spokeswoman, GlaxoSmithKline, Philadelphia; Feb. 9, 2009, Archives of Internal Medicine


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy